The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Prevention and early detection of prostate cancer.

På svenska

Author

  • Jack Cuzick
  • Mangesh A Thorat
  • Gerald Andriole
  • Otis W Brawley
  • Powel H Brown
  • Zoran Culig
  • Rosalind A Eeles
  • Leslie G Ford
  • Freddie C Hamdy
  • Lars Holmberg
  • Dragan Ilic
  • Timothy J Key
  • Carlo La Vecchia
  • Hans Lilja
  • Michael Marberger
  • Frank L Meyskens
  • Lori M Minasian
  • Chris Parker
  • Howard L Parnes
  • Sven Perner
  • Harry Rittenhouse
  • Jack Schalken
  • Hans-Peter Schmid
  • Bernd J Schmitz-Dräger
  • Fritz H Schröder
  • Arnulf Stenzl
  • Bertrand Tombal
  • Timothy J Wilt
  • Alicja Wolk
Show all

Summary, in English

Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.

Publishing year

2014

Language

English

Pages

484-492

Publication/Series

The Lancet Oncology

Volume

15

Issue

11

Document type

Journal article review

Publisher

Elsevier

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 1474-5488